The interpretation of preclinical data in predicting bisphosphonate response in the treatment of osteoporosis.
Individual bisphosphonates for the treatment of osteoporosis are often compared on the basis of preclinical variables such as potency, selectivity, therapeutic index, and effects on fracture healing. The present review examines the methodology and results of preclinical studies providing these types of data for the bisphosphonate etidronate and compares them with the available preclinical data for other bisphosphonates. Analysis of the preclinical data in relation to the results of long-term clinical trials reveals that widely reported differences in preclinical variables for the different bisphosphonates are not significant once dosages and treatment regimens have been optimized for therapeutic use in the clinic.
Ringe
J D
JD
Klinikum Leverkusen, University of Cologne, Germany.
D000818:Animals; D003627:Data Interpretation, Statistical; D004164:Diphosphonates / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D012968:Etidronic Acid / Q000494:pharmacology; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D011237:Predictive Value of Tests; D051381:Rats
D004164:Diphosphonates; D012968:Etidronic Acid